Introduction {#sec1}
============

In recent years, genetic research has been widely used in many medical specialties, in both the diagnosis and risk stratification algorithms of diverse pediatric and adult diseases \[[@cit0001]--[@cit0004]\]. In terms of neurological pathology in children, hereditary disorders are relatively frequent in the pediatric population, and more common than those found in adults \[[@cit0005]\].

Epilepsy is a condition that affects an estimated 10.5 million children worldwide, and idiopathic generalized epilepsies (IGE) represent around 1/3 of all epilepsies. There is increasing evidence that genetic factors play an important role in the development of idiopathic epilepsy; this is mostly based on epidemiological studies, including those of familial aggregation, monozygotic twins and families with a history of epilepsy \[[@cit0006]\]. Of these, IGE seems to have the most significant hereditary component \[[@cit0006]--[@cit0008]\]. In the last decade an increasing number of reports have appeared on rare forms of idiopathic epilepsy with proven Mendelian inheritance \[[@cit0009]\]. These types of epilepsies are characterized by recurrent generalized seizures with childhood- or adolescence-onset, usually in patients with normal development, and no neurological impairment or structural lesions detectable by imaging \[[@cit0010]\]. The syndromes include juvenile myoclonic epilepsy, childhood absence epilepsy, juvenile absence epilepsy, and primary generalized tonic-clonic seizures. The seizures have specific clinical characteristics in each individual syndrome, and typical electroencephalographic (EEG) epileptiform discharges.

Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the adult brain, acting through two classes of specific receptors: GABA~A~ and GABA~B~; these are molecular targets for anticonvulsant drugs, either through a direct action or an increase in GABA levels \[[@cit0011]\]. The GABA~A~ receptor is the most common type of receptor found in the brain, with specific binding sites for benzodiazepines and barbiturates \[[@cit0012], [@cit0013]\]. Functional changes of GABA~A~ and GABA~B~ receptors have been identified in both human epilepsy and animal models of the disease \[[@cit0014]--[@cit0016]\]. Genes encoding the α1, β2 and γ2 subunits of the receptor (GABRA1, GABRB2 and GABRG2) might have a role in the onset of IGE because of the extended distribution of these receptors throughout the central nervous system, the possibility to produce postsynaptic inhibition, and the potential modulation of common antiepileptic drugs' action \[[@cit0012]\]. Various reports claim an association of mutations in the genes encoding GABA~A~ receptors with monogenic forms of IGE \[[@cit0010], [@cit0017]\]. To date, epilepsy-causing mutations have been identified in subunits α1, γ2, β3 and δ \[[@cit0018]\]. These studies suggest that functional loss of the genes encoding the GABA~A~ receptor is an important mechanism in the pathogenesis of epileptic syndromes that have genetic determinism, and although many other mechanisms are involved in the pathogenesis of IGE, these findings provide important insights into the development of these "idiopathic epilepsies" \[[@cit0010]\]. Recently identified mutations in the γ2 subunit of the GABA receptor, with the encoding gene located on the long arm of chromosome 5 (5q34), were reported in two families: in the first case the phenotype described was compatible with generalized epilepsy with febrile seizures plus (GEFS+), while in the second case the phenotype was characteristic for childhood absence epilepsy with febrile seizures plus \[[@cit0019], [@cit0020]\]. Also several studies have found the association of mutations in this gene with IGE and febrile seizures (FS) \[[@cit0021]\].

The main objective of this study was to assess two single nucleotide polymorphisms of the gene encoding the GABRG2 protein -- GABRG2 (3145 G\>A) and GABRG2 rs 211037 Asn196Asn (C588T) -- in a cohort of pediatric patients from Romania, based on the hypothesis that these polymorphisms are potential predictive markers in generalized convulsive seizures and FS. The possible impacts of these polymorphisms on drug-resistant forms of generalized epilepsy and recurrent FS were evaluated as secondary objectives.

Material and methods {#sec2}
====================

The study had a case-control design, and was approved by the local Ethics Committee. All legal caregivers signed an informed consent form for participating in the study.

Patient selection {#sec2.1}
-----------------

The study included a cohort of 114 children hospitalized in a local Clinic of Pediatric Neurology and Psychiatry, or treated in the wards and outpatient centers of the Pediatric Neuropsychiatry Service between May 2011 and October 2013. These cases were divided into two groups: patients with IGE (group 1, 60 patients aged 2--17 years) and patients with FS (group 2, 54 children aged 1.5--5 years).

Epilepsy was confirmed by a history of at least 2 unprovoked seizures (except FS, single episodes of seizures and seizures occurring in the neonatal period), accompanied by specific EEG epileptiform changes, in a patient with normal neurological development and normal neurological examination, and no structural lesions detectable by imaging. Patients with an uncertain diagnosis, a single episode of seizure, provoked seizures, secondary epilepsies or psychiatric disorders were excluded from the study; noncompliant patients were also excluded.

Subgroup with generalized recurrent seizures {#sec2.2}
--------------------------------------------

Patients were divided based on the response to antiepileptic medication in order to identify predictive factors for developing recurrent-type epileptic seizures or repeated FS. The definition of drug resistance was based on the recommendations of the International League Against Epilepsy \[[@cit0022]\] -- no control of seizures during a year of well-directed treatment in appropriate doses and combinations.

Control group {#sec2.3}
-------------

The control group consisted of 153 children aged 2--17 years, hospitalized in the Clinic of Pediatric Neurology and Psychiatry or other pediatric services with no neurological disorders, mental illness, or personal/family history of seizures.

Molecular analysis {#sec2.4}
------------------

Peripheral blood samples (2 ml) collected from both cases and controls were kept at 4ºC until DNA extraction, and stored at --20ºC afterwards, before processing. For polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, DNA was isolated using the Zymo Beads Genomic DNA extraction commercial kit (Zymo Research) according to the manufacturer's instructions, followed by DNA amplification by PCR and fragmentation by enzymatic digestion using specific restriction enzymes. Digestion products were stained with ethidium bromide (Promega, USA), followed by gel electrophoresis in 2% agarose in a UV transillumination system coupled with a camera for image capture (Vilber Lourmat Imaging System). [Table I](#t0001){ref-type="table"} presents the primer sequences needed for amplification, specific restriction enzymes and fragment lengths.

###### 

Sequences of primers, restriction enzyme and length of obtained fragments

  -------------------------------------------------------------------------------------------------------------------
  SNP           Sequencing primer                                Fragments                       Restriction enzyme
  ------------- ------------------------------------------------ ------------------------------- --------------------
  GABGRG2\      Fw: 5'-AGA AAT TTA CCA ACT GGT CTA GCC GG-3'\    AA\                             Ncil
  (3145 G\>A)   Rev: 5'-AAA TCA AAT ATT GTG TCA TGC TTA GT -3'   AG\                             
                                                                 GG                              

  GABGRG2\      Fw: 5'-GAG TGC CAA TTA CAA TTG CAA AA-3'\        CC: 122 bp\                     Apol
  (211037)\     Rev: 5'-AAT CAG AAA GAC TGT AGG TGA GG-3'        CT: 122 bp + 100 bp + 22 bp;\   
  Asn196Asn\                                                     TT: 100 + 22 bp                 
  C588T)                                                                                         
  -------------------------------------------------------------------------------------------------------------------

The protocol was based on the methodology described by Chou *et al.* \[[@cit0016]\], with a few adaptations: initial denaturation for 5 min at 95°C was followed by 37 cycles (for GABGRG2 3145 G\>A) or 35 cycles (for GABGRG2 Asn196Asn) of denaturation for 30ˊˊ at 94°C, attachment of primers (annealing) for 30ˊˊ at 60°C for GABGRG2 3145 G\>A and 55°C for GABGRG2 Asn196Asn, then extension for 45ˊˊ at 72°C, with a final extension for 7ˊ at 72°C in both cases. As C to T substitution at nucleotide position 588 in exon 5 of the GABRG2 gene creates a restriction site for ApoI (the restriction enzyme), results were interpreted based on the disappearance of a restriction site in the C allele (122 bp) compared to the T allele (100 bp + 22 bp), shown schematically in [Figure 1 A](#f0001){ref-type="fig"} (the fragment with \< 100 bp is not visible after electrophoresis). [Figure 1 B](#f0001){ref-type="fig"} presents the genotypes for GABRG2 locus C588T, after amplification, enzymatic digestion and electrophoresis.

![**A** -- Fragment lengths after enzymatic digestion (GABRG2 C588T); **B** -- genotypes for GABRG2 locus C588T, after amplification, enzymatic digestion (with ApoI) and electrophoresis in agarose gel\
M -- marker; 1, 2, 4, 5, 6, 7, 9 -- CC, 8 -- CT, 3 -- TT.](AMS-14-28749-g001){#f0001}

Statistical analysis {#sec2.5}
--------------------

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS, version 17, Chicago, IL, USA), with data considered as normal or quantitative variables. Frequencies were used for normal variables, while quantitative variables were tested for normal distribution using the Kolmogorov-Smirnov test, and characterized by median and percentages (25--75%) or mean and standard deviation (SD) when appropriate. The χ^2^ test was used for comparing more than 2 variables and calculating the Hardy-Weinberg equilibrium. The odds ratio (OR) and 95% confidence interval (CI) were calculated to demonstrate the probability or susceptibility of the association of gene polymorphisms with treatment-resistant epilepsies. Statistical significance was set at *p* \< 0.05. Quantitative variables were compared using the Mann-Whitney test \[[@cit0023]\].

Results {#sec3}
=======

Assessing the frequency of GABRG2 polymorphisms in children with epilepsy {#sec3.1}
-------------------------------------------------------------------------

Distribution of GABRG2 rs211037 and GABRG2 G\>A in nucleotide position 3145 in all groups met Hardy-Weinberg equilibrium conditions. The frequencies for the polymorphisms of these mutations were determined for the first time in a population from Romania, and are presented in [Figure 2](#f0002){ref-type="fig"}. [Tables II](#t0002){ref-type="table"} and [III](#t0003){ref-type="table"} present allele frequency and genotype distribution of GABRG2 C588T in groups 1 and 2 -- patients with the T allele and homozygous for the TT variant were strongly predisposed to developing FS when compared to those with a CC genotype.

###### 

Allele frequency and genotype distribution of GABRG2 C588T in the epilepsy, febrile seizures and control groups

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genotype\        Generalized epilepsy vs. control\                                     Febrile seizures vs. control\
  GABRG2 C588T     χ^2^ *p*-value, OR, 95% CI                                            χ^2^ *p*-value; OR, 95% CI
  ---------------- --------------------------------------------------------------------- ------------------------------------------------------------------------
  CC vs. CT        *p* = 0.82, OR = 1.07, 0.57--2.02                                     *p* = 0.008[\*](#tf2-1){ref-type="table-fn"}, OR = 2.77, 1.28--6.001

  CC vs. TT        *p* = 0.60, OR = 0.74, 0.25--2.20                                     *p* \< 0.0001[\*](#tf2-1){ref-type="table-fn"}, OR = 6.97, 2.84--17.13

  C vs. T          *p* = 0.77, OR = 0.93, 0.58--1.49                                     *p* \< 0.0001[\*](#tf2-1){ref-type="table-fn"}, OR = 2.95, 1.87--4.64

  CC vs. CT + TT   *p* = 0.001[\*](#tf2-1){ref-type="table-fn"}, OR = 0.26, 0.11--0.60   *p* = 0.0002[\*](#tf2-1){ref-type="table-fn"}, OR = 0.26, 0.13--0.54

  TT vs. CT + CC   *p* = 0.0009[\*](#tf2-1){ref-type="table-fn"}, OR = 5.5, 1.87--16.1   *p* = 0.0002[\*](#tf2-1){ref-type="table-fn"}, OR = 4.00, 1.87--8.53
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

Statistically significant, OR -- odds ratio, CI -- confidence interval.

###### 

Alleles and genotype distribution for GABRG2 in patients from group 1 and controls, and genotype and allele frequency in patients with recurrent seizures

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genotype 3145 GABRG2     Group 1 *N* (%)                                                Control group *N* (%)                                           χ^2^ test *p*-value, OR, 95% CI                                       
  ------------------------ -------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------- -----------------------------------------------------------------------
  AA                       27 (45.0)                                                      38 (24.8)                                                       --                                                                    

  AG                       16 (26.7)                                                      78 (50.9)                                                       *p* = 0.006[\*](#tf3-1){ref-type="table-fn"}, OR = 0.28, 0.13--0.59   

  GG                       17 (28.3)                                                      37 (24.1)                                                       *p* = 0.28, OR = 0.64, 0.30--1.32                                     

  A                        70 (58.3)                                                      154 (50.3)                                                      --                                                                    

  G                        50 (41.7)                                                      152 (49.7)                                                      *p* = 0.13, OR = 0.72, 0.47--1.11                                     

  GG vs. AG + AA           17/43                                                          37/116                                                          *p* = 0.53, OR = 1.24, 0.63--2.43                                     

  AA vs. AG + GG           27/33                                                          38/115                                                          *p* = 0.004[\*](#tf3-1){ref-type="table-fn"}, OR = 0.40, 0.21--0.75   

  **Genotype frequency**   **Drug-resistant forms of idiopathic generalized epilepsy**\   **Well-controlled forms of idiopathic generalized epilepsy**\   **χ^2^ test *p*-value, OR, 95% CI**                                   
                           ***N* = 11**\                                                  ***N* = 49**\                                                                                                                         
                           ***n* (%)**                                                    ***n* (%)**                                                                                                                           

  GABRG2 C588T:                                                                                                                                                                                                                 

                           CC                                                             1 (9.1)                                                         30 (61.2)                                                             --

                           CT                                                             7 (63.6)                                                        17 (34.7)                                                             *p* = 0.02[\*](#tf3-1){ref-type="table-fn"}, OR = 12.35, 1.39--109.13

                           TT                                                             3 (27.3)                                                        2 (4.1)                                                               *p* = 0.002[\*](#tf3-1){ref-type="table-fn"}, OR = 45.0, 3.09--655.33

                           C                                                              9 (40.9)                                                        77 (78.6)                                                             --

                           T                                                              13 (59.1)                                                       21 (21.4)                                                             *p* = 0.001[\*](#tf3-1){ref-type="table-fn"}, OR = 5.29, 1.99--14.07

  GABRG2 G\>A 3145:                                                                                                                                                                                                             

                           AA                                                             6 (54.5)                                                        21 (52.8)                                                             --

                           AG                                                             0 (0.0)                                                         12 (24.5)                                                             --

                           GG                                                             5 (45.5)                                                        16 (32.7)                                                             *p* = 0.89, OR = 1.09, 0.28--4.23

                           A                                                              12 (54.5)                                                       54 (55.1)                                                             --

                           G                                                              10 (45.5)                                                       44 (44.9)                                                             *p* = 0.96, OR = 1.02, 0.40--2.59

  **Genotype frequency**   **Recurrent febrile seizures**\                                **Single episode febrile seizure**\                             **χ^2^ test *p*-value, OR, 95% CI**                                   
                           ***N* = 16**\                                                  ***N* = 38**\                                                                                                                         
                           ***n* (%)**                                                    ***n* (%)**                                                                                                                           

  GABRG2 C588T:                                                                                                                                                                                                                 

                           CC                                                             2 (12.5)                                                        10 (26.3)                                                             --

                           CT                                                             3 (18.7)                                                        22 (57.9)                                                             *p* = 0.85, OR = 0.45, 0.05--3.70

                           TT                                                             11 (68.8)                                                       7 (18.4)                                                              *p* = 0.04[\*](#tf3-1){ref-type="table-fn"}, OR = 7.85, 1.31--47.06

                           C                                                              7 (21.9)                                                        42 (53.8)                                                             --

                           T                                                              25 (78.1)                                                       36 (46.2)                                                             *p* = 0.004[\*](#tf3-1){ref-type="table-fn"}, OR = 4.16, 1.61--10.76
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Statistically significant, OR -- odds ratio, CI -- confidence interval.

![**A** -- Genotype frequency for the GABRG2 G\>A polymorphism in IGE, **B** -- genotype frequency for the GABRG2 Asn196Asn polymorphism in IGE, **C** -- genotype frequency for the GABRG2 Asn196Asn polymorphism in FS](AMS-14-28749-g002){#f0002}

Assessing GABRG2 polymorphisms in cases of generalized recurrent seizures {#sec3.2}
-------------------------------------------------------------------------

According to their response to antiepileptic medication, 18.3% of patients with IGE had drug-resistant forms of epilepsy and 29.6% of patients with a history of FS had repeated episodes during febrile states triggered by respiratory tract infections ([Table III](#t0003){ref-type="table"}). For those with recurrent seizures, a significant association was found with the TT homozygous genotype and T allele for both FS and epilepsy for the C588T locus, while GABRG2 G\>A 3145 has not been identified as a factor associated with any type of seizure.

Genotype distribution of the two gene polymorphisms in epileptic patients with a history of FS {#sec3.3}
----------------------------------------------------------------------------------------------

When comparing patients in group 1 with and without a history of FS to identify a possible genotype-phenotype correlation, a statistically significant difference was found for the GABRG2 Asn196Asn polymorphism: the TT homozygous genotype was more frequent in patients with a history of FS (*p* = 0.0001). The same comparison showed no significant association for GABRG2-G\>A 3145 ([Table IV](#t0004){ref-type="table"}).

###### 

GABRG2 - Asn196Asn and GABRG2-G\>A 3145 polymorphism in febrile seizures

  *p* = 0.0001         Febrile seizures    Total        *p* = 0.45   Febrile seizures   Total                                       
  -------------------- ------------------- ------------ ------------ ------------------ ------- --------- ------------ ------------ ------------
  GABRG2- Asn196Asn:   GABRG2 G\>A 3145:                                                                                            
   CC                  *N* (%)             3 (25.0)     28 (58.3)    31 (51.7)          AA      *N* (%)   5 (41.7)     22 (45.8)    27 (45.0)
   CT                  *N* (%)             5 (41.7)     19 (39.6)    24 (40.0)          AG      *N* (%)   2 (16.7)     14 (29.2)    16 (26.7)
   TT                  *N* (%)             4 (33.3)     1 (2.1)      5 (8.3)            GG      *N* (%)   5 (41.7)     12 (25.0)    17 (28.3)
  Total                *N* (%)             12 (100.0)   48 (100.0)   60 (100.0)         Total   *N* (%)   12 (100.0)   48 (100.0)   60 (100.0)

Genotype distribution of the two gene polymorphisms in epileptic patients by sex {#sec3.4}
--------------------------------------------------------------------------------

For patients with IGE the GG genotype was more frequently found in girls (43.3%) and the AA genotype was more frequent in boys (63.3%). In the control group, the AA homozygous genotype was representative in girls (30%), whereas the AG heterozygous genotype was dominant in boys (69.8%), with a significant difference in both cases (*p* = 0.001). For the GABRG2 Asn 196 Asn variant, genotype distribution between the sexes showed no statistical significance ([Table V](#t0005){ref-type="table"}).

###### 

GABRG2 G\>A 3145 and GABRG2 Asn 196 Asn polymorphism by gender

  --------------------------------------------------------------------------------------------------------------
  Patient groups            Gender               Total                                               
  ------------------------- -------------------- ----------- ------------ ------------ ------------- -----------
  Cases (groups 1 and 2)\   GABRG2 INTRON        AA          *N* (%)      8 (26.7)     19 (63.3)     27 (45.0)
  *p* = 0.001                                                                                        

  AG                        *N* (%)              9 (30.0)    7 (23.3)     16 (26.7)                  

  GG                        *N* (%)              13 (43.3)   4 (13.3)     17 (28.3)                  

  Total                                          *N* (%)     30 (100.0)   30 (100.0)   60 (100.0)    

  Controls\                 GABRG2 INTRON        AA          *N* (%)      27 (30.0)    11 (17.5)     38 (24.8)
  *p* = 0.001                                                                                        

  AG                        *N* (%)              34 (37.8)   44 (69.8)    78 (51.0)                  

  GG                        *N* (%)              29 (32.2)   8 (12.7)     37 (24.2)                  

  Total                                          *N* (%)     90 (100.0)   63 (100.0)   153 (100.0)   

  Cases (groups 1 and 2)\   GABRG2 Asn 196 Asn   CC          *N* (%)      11 (36.7)    20 (66.7)     31 (51.7)
  *p* = 0.052                                                                                        

  CT                        *N* (%)              15 (50.0)   9 (30.0)     24 (40.0)                  

  TT                        *N* (%)              4 (13.3)    1 (3.3)      5 (8.3)                    

  Total                                          *N* (%)     30 (100.0)   30 (100.0)   60 (100.0)    

  Controls\                 GABRG2 Asn 196 Asn   CC          *N* (%)      39 (43.3)    40 (63.5)     79 (51.6)
  *p* = 0.07                                                                                         

  CT                        *N* (%)              38 (42.2)   19 (30.2)    57 (37.3)                  

  TT                        *N* (%)              13 (14.4)   4 (6.3)      17 (11.1)                  

  Total                                          *N* (%)     90 (100.0)   63 (100.0)   153 (100.0)   
  --------------------------------------------------------------------------------------------------------------

Genotype-haplotype combinations (linked analysis of the two polymorphisms in the IGE group) {#sec3.5}
-------------------------------------------------------------------------------------------

In order to identify an association linking the two polymorphisms with seizures, a composite analysis of several genotypes was performed. Of the nine possible variants, associations with epilepsy were found for CC-AG (*p* = 0.02) and CT-AG (*p* = 0.007), using the CC-AA combination as a reference ([Table VI](#t0006){ref-type="table"}).

###### 

Haplotypes in the control and epilepsy groups

  GABRG2 C588T-GABRG2 INTRON   Patient groups   χ^2^ test *p*-value, OR, 95% CI                                                                                      
  ---------------------------- ---------------- --------------------------------- ------------ --------------------------------------------------------------------- -----------
  Haplotypes                   CC-AA            *N* (%)                           17 (28.3)    23 (15.0)                                                             Reference
  CC-AG                        *N* (%)          11 (18.3)                         43 (28.1)    *p* = 0.02[\*](#tf6-1){ref-type="table-fn"}, OR = 0.34, 0.13--0.86    
  CC-GG                        *N* (%)          3 (5.0)                           13 (8.5)     *p* = 0.09, OR = 0.31, 0.07--1.27                                     
  CT-AA                        *N* (%)          10 (16.7)                         8 (5.3)      *p* = 0.35, OR = 1.69, 0.55--5.19                                     
  CT-AG                        *N* (%)          5 (8.3)                           30 (19.6)    *p* = 0.007[\*](#tf6-1){ref-type="table-fn"}, OR = 0.22, 0.07--0.70   
  CT-GG                        *N* (%)          9 (15.0)                          19 (12.4)    *p* = 0.38, OR = 0.64, 0.23--1.76                                     
  TT-AA                        *N* (%)          0                                 7 (4.6)      --                                                                    
  TT-AG                        *N* (%)          0                                 5 (3.2)      --                                                                    
  TT-GG                        *N* (%)          5 (8.3)                           5 (3.2)      *p* = 0.66, OR = 1.35, 0.33--5.42                                     
  Total                                         *N* (%)                           60 (100.0)   153 (100.0)                                                           

Statistically significant, OR -- odds ratio, CI -- confidence interval.

Discussion {#sec4}
==========

Triggered by a rising fever without a proven central nervous system infection, FS are non-epileptic critical events occurring in children aged 6 months to 5 years, and represent the most common cause of seizures in childhood, with an incidence of 2--5% \[[@cit0006]\]. In spite of adequate treatment, FS may be recurrent in 30% of cases, with a 2--3% risk of developing subsequent epilepsy. Understanding the mechanism of recurrent seizures is paramount for their management. Although the etiology of FS is not clear, genetic factors seem to play a role in triggering them \[[@cit0006], [@cit0011], [@cit0015]\]. As the incidence of seizures in first degree relatives can reach 30%, most authors consider FS a polygenic or multifactorial condition, with a possible autosomal dominant inheritance with incomplete penetrance \[[@cit0006], [@cit0008], [@cit0024]--[@cit0026]\].

The incidence of FS varies worldwide, with a lower incidence in Western Europe and the United States (2--5%) compared to Asia (5--10% in India, and 9% in Japan). Published evidence showed that the CC genotype for GABRG2 (rs211037) polymorphism in Asians with FS is frequent compared to controls; however, no such difference was identified in Caucasians. Thus it is possible that the CC genotype acts as a causal factor for the development of FS in Asians (Chinese and Egyptians), but not in Caucasians, perhaps due to differences in environmental factors, gene pool, or the linkage of this polymorphism with other variants with risk of epilepsy \[[@cit0027]--[@cit0030]\]. Nevertheless, further research is needed to clarify these aspects. A large number of genes have been discussed as potentially involved in the hereditary transmission of FS \[[@cit0030]\]. From these, several mutations in the γ2 subunit of the GABA~A~ receptor were reported to be associated with FS (2- (R43Q), 2 (K289M), 2 (Q351X), and 2 (IVS6 + 2 T -\> G)) \[[@cit0019], [@cit0020], [@cit0031]\].

Through a comparative analysis of genotypes in patients with IGE and healthy patients, our results revealed that the GABRG2 polymorphism in the intronic position 3145G\>A is not associated with an increased risk of epilepsy. Based on published literature, the AA genotype was taken as a reference; for this genetic locus, GG and AG genotype frequency was 75% of the variants identified in the control group, while in the group of patients with epilepsy these genotypes were present in 55% of cases. Still, it is noteworthy that the A allele frequency was about 58.3% in the epilepsy group, close to that of the control group (50.3%). As opposed to this, the AG heterozygous genotype was statistically significant in the epilepsy group (*p* = 0.006), with the same association noted in the dominant model (AA vs. AG + GG). In both situations, OR values were \< 1, meaning that patients with a G-allelic variant present minimal risk of developing epilepsy ([Table III](#t0003){ref-type="table"}). The frequency of alleles A and G of this polymorphism were represented in similar proportions in the IGE group and in controls, the same being noted after redistributing the patients based on therapeutic control of seizures (recurrent seizures vs. good therapeutic control). Thus this polymorphism had no statistically significant association in the present study.

The distribution of genotypes and allele frequencies for GABRG2 (rs211037) in the three groups of patients showed significant differences, especially in patients with FS ([Figure 2](#f0002){ref-type="fig"}). The most frequent genotype in group 1 was CC (51.6%), while in group 2 it was CT heterozygotes (44.4%). These results are in contradiction to those reported by Chou *et al.* \[[@cit0032]\] in which CT heterozygotes were most frequently identified between epilepsy patients and TT homozygotes in those with FS. Compared to the control group, we observed differences in both cases, with a slightly superior CT frequency in epileptics vs. controls (40% and 37.2%), and the same frequency of CC homozygotes in cases and controls. When comparing patients with and without FS, we found statistically significant differences, the frequency of CT heterozygous and TT homozygote genotypes being superior to that identified in controls. Comparing CT or TT genotype frequency to that of the CC genotype (reference genotype for GABRG2 Asn196Asn polymorphism), we found no risk associated with the development of epilepsy, again in contradiction to the results of Chou *et al.* \[[@cit0032]\] In contrast, recessive model C allele carriers (TT vs. CT + CC genotypes) have been identified as having an about 5.5 times higher risk for developing epilepsy compared to those with a T allele genotype (*p* = 0.0009).

In 2013, Haerian *et al.* conducted a comprehensive meta-analysis of 8 studies published between 2002 and 2011 on populations of different origin from Asia, Europe and America assessing the GABRG2 rs211037 genotype distribution in patients with epilepsy, FS and healthy populations \[[@cit0033]\]. Of these only 3 studies supported the hypothesis that synonymous GABRG2 rs211037 polymorphism is a predictive factor in causing epilepsy or FS in children: an Egyptian study with a positive association for FS and two studies from Taiwan associating the polymorphism with FS and IGE. The Egyptian study conducted by Salam *et al.* was based on genotyping 100 blood samples from children with FS and 120 samples from healthy children, showing a strong association between allele C in the 588 position in the GABRG2 gene and developing FS (OR = 2.15, *p* \< 0.0001); the frequency of homozygotes for the wild-type CC allele was significantly higher in those with FS \[[@cit0011]\]. These results are inconsistent with those reported by Ponnala *et al.*, in a study conducted in India on 127 children with FS and IGE, in which T alleles and TT genotypes were identified as associated with FS \[[@cit0034]\] -- our results are in line with these findings. In addition, the distribution was statistically significant for the allelic variant T, associated with IGE in the study by Ponnala *et al.* \[[@cit0034]\] (OR = 2.05, 95% CI: 1.02--4.12; *p* \< 0.05). Although our data did not confirm these results, using a compound model we found an association of allele C in genotypic composition (TT vs. CC + CT) with increased susceptibility to develop IGE. The TT genotype carriers were significantly representative in the group with recurrent FS compared to controls, the same being noted for IGE. Our data showed that GABRG2 588T allele carriers have a 5 times increased risk of developing seizures compared to others, and TT homozygotes and CT heterozygotes have a higher risk of developing recurrent seizures and repeated episodes of FS.

Very few studies have reported comparative analyses of drug-resistant and well-controlled forms of epilepsy. In the study by Ponnala *et al.* \[[@cit0034]\] recurrent crises were strongly associated with the TT genotype, a result that was not confirmed by a similar study published by Kumari *et al.* \[[@cit0035]\]. However, Chou *et al.* \[[@cit0032]\] found an association between GABRG2 (SNP211037) and FS but no association regarding intron position polymorphism of GABRG2 rs211014, a conclusion that is in accordance with our results. Still, Wang *et al.* found an association between the intronic polymorphism of GABRG2 and FS in a population in Southern China, where the presence of the A allele was observed with a higher incidence \[[@cit0036]\]. In another study by Chou *et al.* \[[@cit0016]\] the CC genotype was found more frequently in those who developed IGE compared to healthy individuals. These results were also confirmed by Kumari *et al.*, who sought GABRG2 association between polymorphism (rs211037) and the development of epilepsy or recurrent seizures \[[@cit0035]\].

Allele frequency for the GABRG2 rs211037/C588T/Asn196Asn polymorphism showed differences in geographic distribution, race and origin of selected populations. An allelic distribution similar to that found in our study was reported in populations of Japanese and Chinese origin, as well as some European populations, with the T allele being more frequently highlighted in those with seizures (either IGE, FS, or both); these results are inconsistent with allele frequencies identified in populations from India, Germany and Nigeria \[[@cit0037]--[@cit0039]\].

Our study is limited by the relatively small number of patients, which could cause false positive results, especially given the fact that in genetic research, sample size is a determining factor, essential for the study's power to detect causal variants in genetic association found in polygenic, multifactorial diseases. The small sample size is due to the fact that not all caregivers signed the informed consent, and neuroimaging investigations were not widely used. Also, as patients with FS are not usually hospitalized, only a few agreed to return for blood sampling.

Nevertheless, the results show a strong, statistically significant association of the T allele and the TT homozygote genotype of GABRG2 C588T with FS. To our knowledge, this is the first study on a pediatric population from Romania that found an association of GABRG2 gene polymorphism with FS. The results suggest that individuals with the T allele genotype variant have a real risk of recurrent FS, while patients with IGE and a T allele variant or CT or TT genotype have a high risk of developing a multidrug-resistant form of epilepsy.

In conclusion, C588T polymorphism of the GABRG2 gene might be a predictive genetic marker in triggering febrile convulsions. GABRG2 rs211037 TT homozygotes and T allele variants have an increased risk of developing FS (*p* = 0.001). Recurrent crises and repeated episodes of FS are found more often in those with GABRG2 Asn196Asn TT genotype polymorphism -- in these cases, the risk for developing IGE is 45 times higher, and the risk of recurrent FS is about 8 times higher compared to individuals without this polymorphism (*p* = 0.002 and *p* = 0.04 respectively). Further studies are needed to explain the association between other unique polymorphisms of the GABRG2 gene and FS, as well as the genotype-phenotype relationship of FS in children.
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